What is the difference between Argireline and KGF-1?

Argireline: Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects KGF-1: Binds FGFR2b (the KGF receptor), which is exclusively expressed on epithelial cells — providing tissue-specific action without mesenchymal effects.

Is Argireline FDA approved?

Argireline is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is KGF-1 FDA approved?

KGF-1 is FDA approved (FDA status current as of 2004-12-15). This regulatory status is provided for research and educational context only.

How is Argireline administered in research settings?

In research settings, Argireline is typically administered via the topical route. PeptideBase does not provide dosing or administration instructions.

How is KGF-1 administered in research settings?

In research settings, KGF-1 is typically administered via the subcutaneous or topical routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Argireline vs KGF-1

Peptide Comparison

Argireline vs KGF-1

Both are Skin & Cosmetic peptides.

Argireline

Acetyl Hexapeptide-3

Skin & JointNot EvaluatedResearch Only

Half-life: N/A (topical)

18 providers listed

Full Argireline profile →

KGF-1

FGF-7

Skin & JointFDA ApprovedResearch Only

No providers listed yet

Full KGF-1 profile →

Bottom line

KGF-1 is FDA-approved, while Argireline is not evaluated — the clearest structural difference between them.

Quick Verdict

Argireline

Evidence

Clinical

KGF-1

Evidence

Emerging Clinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Argireline
Further along in FDA review	KGF-1
More provider options (18 vs 0)	Argireline

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Argireline

KGF-1

Mechanism Family

Skin & Cosmetic

Half-life

N/A (topical)

—

FDA Status

not evaluated

approved

Admin Routes

topical

subcutaneous, topical

Availability

Research Only

Providers

18 listed

None listed

FDA Update

—

Dec 2004

Avail. Notes

Cosmetic peptide (acetyl hexapeptide-3). Sold as cosmetic ingredient by Lipotec/Sederma. Not regulated as a drug by FDA. No NDA or IND. Cosmetic anti-wrinkle ingredient only.

—

Research Evidence

Argireline

ClinicalRCT · 3 key studies · most recent 2026

KGF-1

Emerging ClinicalRCT · 1 key study · dated evidence base — most recent 2004

Research Citations

Argireline

RCT2013 · American Journal of Clinical Dermatology

The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-…

Cohort2026 · Biomater Adv

DES-mediated self-assembled polypeptides: Synergistic neuromuscular signaling inhibition for anti-aging.

RCT2017 · Journal of Cosmetic Dermatology

The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3: a prospective, ra…

KGF-1

RCT2004 · New England Journal of Medicine

Palifermin for oral mucositis after intensive therapy for hematologic cancers

About Argireline

Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects

Research Areas

SNARE complex (SNAP-25) competitive inhibition reducing expression line depthwrinkle reduction documented in controlled human trialstopical cosmetic application — not a systemic peptidesoftening of dynamic lines over 4–8 weeks at 5–10% concentration

About KGF-1

Binds FGFR2b (the KGF receptor), which is exclusively expressed on epithelial cells — providing tissue-specific action without mesenchymal effects. Activates RAS/MAPK and PI3K/Akt to promote keratinocyte proliferation and migration. Extends the anagen phase of the hair growth cycle.

Research Areas

wound healinghair growthkeratinocyte proliferationmucosal repairepithelial protection

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Argireline

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

KGF-1

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Argireline

18 listed

Browse directory →

Providers offering

KGF-1

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.